Blast Clearance Dynamics and Time to Response Across <i>IDH1-</i> and <i>IDH2</i>-Mutated AML.

ABSTRACT:

Background

IDH mutations are found in 15%-20% of acute myeloid leukemia (AML). Recent evidence suggests that IDH mutation subtypes may respond differently to intensive chemotherapy. We evaluated blast clearance patterns, remission outcomes, and overall survival (OS) in AML patients with IDH2 R140, IDH2 R172, and IDH1 R132 mutations to assess differences in treatment response.

Methods

We retrospectively reviewed AML patients diagnosed at Mayo Clinic, Rochester (2016-2023) with NGS data and treated with intensive chemotherapy (7+3 or CPX-351). Bone marrow blasts were assessed at diagnosis, mid-induction, and end-of-cycle; blast clearance was defined as < 5%. Composite remission (CRc) included CR/CRi per ELN 2022. IDH2 responders were c

SUBMITTER: Najeeb MS 

PROVIDER: S-EPMC12703798 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature